ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2643

HO-1 Expression in Monocytes Might Regulate Kidney Damage in Lupus Nephritis Patients

Loreto Cuitino1,2, Javiera Obreque1,2, Patricia Gajardo-Meneses1,2, Gonzalo P. Méndez2,3, Alexis M. Kalergis2,4 and Carolina Llanos1,2, 1Departamento de Inmunología Clínica y Reumatología, Santiago, Chile, 2Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 3Departamento de Anatomía Patológica, Santiago, Chile, 4Millennium Institute on Immunology and Immunotherapy and Departamento de Endocrinología, Santiago, Chile

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: innate immunity, monocytes and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: It is well established that up to 70% of systemic lupus erythematosus (SLE) patients will develop Lupus Nephritis (LN). Recent studies have revealed that infiltrating monocytes and macrophages are associated with LN pathogenesis. Studies by our group and others have studied the potential role of HO-1, a haem-degrading enzyme with anti-inflammatory properties, in the modulation of immune cells and SLE development. Therefore, we decided to explore the contribution of HO-1 expression to LN pathogenesis.

Methods: All patients were recruited at Hospital Clínico of Pontificia Universidad Católica de Chile, fulfilled the ACR SLE classification criteria and had proliferative LN confirmed by renal biopsy (Class III, IV or V ISN/RPS). All individuals signed an informed consent form. Monocytes were purified using pan-monocytes MACS kit from peripheral blood mononuclear cells (PBMCs) of LN patients and healthy controls (HC). The CD16+ inflammatory monocytes were quantified. FACS was used to measure phagocytosis, HO-1 expression and ROS levels. The latter were determined using a CellRox Kit.

Results: We found that monocytes purified from LN patients show significant differences as compared to healthy controls (HC) in all parameters analyzed. LN patients have increased the CD16+ inflammatory monocytes (LN: 6.72±0.98%, HC: 4.07±0.48%; p<0.05). HO-1 protein expression is decreased in monocytes from LN patients compared with HC (LN: 1572±481, HC: 4789±911; p=0.005). ROS levels are elevated in LN monocytes showing similar values to monocytes from HC treated with a ROS inducer (HC: 3509±584, HC+TBHP: 8436±1909, LN: 8355±1714). Furthermore, the phagocytic activity is increased in LN monocytes (77.97±3.31%) compared to HC (39.63±2.75%). Moreover, our preliminary data indicate that HO-1 induction leads to down regulation of ROS production in LN (~60%) and HC (~40%) leaving both in similar ROS production. In addition, phagocytic activity is also decreased in LN and HC monocytes in the presence of HO-1 inducer (~30%). Furthermore, in renal biopsies of LN patients we observed that HO-1 expression is increased in renal tubular epithelial cells compared to HC.

Conclusion: Decreased HO-1 expression in circulating monocytes of LN patients leads to higher ROS production and higher phagocytic activity, which contributes to renal injury. We propose that increased HO-1 levels in epithelial renal cells might be an attempt of the kidney to protect itself from damage. Since ROS levels and phagocytosis are reduced when a HO-1 inducer is used, we also speculate that HO-1 induction in monocytes might exert a cytoprotective role in LN by regulating innate immunity. FONDECYT N°1150173.

Acknowledgements: We would like to extend our appreciation to all the volunteers that participated in this study.


Disclosure: L. Cuitino, None; J. Obreque, None; P. Gajardo-Meneses, None; G. P. Méndez, None; A. M. Kalergis, None; C. Llanos, None.

To cite this abstract in AMA style:

Cuitino L, Obreque J, Gajardo-Meneses P, Méndez GP, Kalergis AM, Llanos C. HO-1 Expression in Monocytes Might Regulate Kidney Damage in Lupus Nephritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/ho-1-expression-in-monocytes-might-regulate-kidney-damage-in-lupus-nephritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ho-1-expression-in-monocytes-might-regulate-kidney-damage-in-lupus-nephritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology